Breaking News Instant updates and real-time market news.

MYL

Mylan

$36.53

-0.33 (-0.90%)

, NVS

Novartis

$85.80

0.65 (0.76%)

07:32
12/01/17
12/01
07:32
12/01/17
07:32

Wells not seeing Amazon talks as good news for Mylan, others

CNBC last night reported that Amazon.com (AMZN) is in exploratory talks with Mylan (MYL) and Novartis' Sandoz (NVS) regarding a potential entry into the pharmacy space. While the market might consider this good news for Mylan and other generics as a sign of potential preferred supplier agreements, Wells Fargo analyst David Maris says he's more cautious. Amazon entering the pharmacy market could be a negative headwind for retail generics and potentially branded over-the-counter products, Maris argues. He believes Amazon would source at competitive prices and that "increased price transparency may cause traditional retailers to push harder for price concessions."

MYL

Mylan

$36.53

-0.33 (-0.90%)

NVS

Novartis

$85.80

0.65 (0.76%)

AMZN

Amazon.com

$1,176.75

15.48 (1.33%)

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 18

    Jan

  • 18

    Mar

  • 17

    May

MYL Mylan
$36.53

-0.33 (-0.90%)

10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
11/07/17
RBCM
11/07/17
NO CHANGE
Target $37
RBCM
Sector Perform
Mylan price target raised to $37 from $32 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Mylan to $37 and kept his Sector Perform rating. The analyst says that in spite of two consecutive challenging quarters that showed the company is not immune to broader sector challenges, Mylan's relative positioning remains favorable to peers, adding that generic Copaxone performance is helpful in the near term.
11/07/17
SUSQ
11/07/17
NO CHANGE
Target $47
SUSQ
Positive
Mylan positioned to deliver near-term growth, says Susquehanna
Susquehanna analyst Andrew Finkelstein believes Mylan is favorably positioned relative to peers to deliver near-term growth despite headwinds while advancing a long-term strategy. He said the shares warrant a premium to traditional peers who face tougher growth challenges. Finkelstein reiterated his Positive rating and raised his price target to $47 from $43 on Mylan.
10/31/17
WELS
10/31/17
NO CHANGE
WELS
Market Perform
Wells sees 'substantial headline risk' for Mylan from probe
Today's expanded collusion probe into generic price fixing will be a "significant overhang" for several generic drug manufacturers, Wells Fargo analyst David Maris tells investors in an intraday research note. For Mylan (MYL), the specific addition of Rajiv Malik, the company's second-highest-ranking executive, creates "substantial headline risk," and may prove to be a distraction to someone many consider one of the key operational managers, Maris adds. He believes the expanding probe will cause many investors to steer clear of an already struggling sector. The analyst has Market Perform ratings on both Mylan and Teva (TEVA). Mylan in midday trading is down 7% to $35.59.
NVS Novartis
$85.80

0.65 (0.76%)

11/20/17
JPMS
11/20/17
DOWNGRADE
Target $82
JPMS
Neutral
Advanced Accelerator downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jessica Fye downgraded Advanced Accelerator Applications (AAAP) to Neutral citing the proposed Novartis (NVS) tender offer. The analyst says the stock is already reflecting a very high likelihood of the deal closing. She raised her price target for the shares to $82 from $53.
12/01/17
SBSH
12/01/17
DOWNGRADE
Target $380
SBSH
Neutral
Regeneron downgraded to Neutral from Buy at Citi
Citi analyst Robyn Karnauskas downgraded Regeneron Pharmaceuticals (REGN) to Neutral and cut her price target for the shares to $380 from $480. The biotechnology company closed yesterday up 1% to $361.86. The analyst believes the competitive threat from Novartis' (NVS) vision-loss drug RTH258 is being underappreciated by the market. It is hard to believe that RTH258 would not have a price impact, at minimum, on Regeneron's Eylea, Karnauskas tells investors in a research note. The analyst points out that her dermatologist survey came back bullish for Regeneron's Dupixent. While she expects the drug to beat expectations for 2018, the analyst feels this won't be enough to offset the overhang on shares from Eylea competition.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/13/17
MSCO
11/13/17
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees limited near-term impact on Regeneron from Novartis data
Morgan Stanley analyst Matthew Harrison noted that Novartis (NVS) presented RTH258 data at the American Academy of Ophthalmology meeting that did show the potential for a commercial "hook," namely an ability to "dry out" hard to treat patients. However, an FDA filing is not expected until the second half of 2018 and key safety details are still needed for a more accurate determination of brolucizumab's possible commercial impact, said Harrison, who sees limited near-term impact on Regeneron (REGN) from the data on the Eylea competitor. He keeps an Equal Weight rating on Regeneron shares.
AMZN Amazon.com
$1,176.75

15.48 (1.33%)

11/30/17
JEFF
11/30/17
NO CHANGE
JEFF
Jefferies sees drugstore sentiment improving with no Amazon news
Investors were anticipating an announcement from Amazon.com (AMZN) regarding a pharmacy strategy around Thanksgiving due to recent media reports and the resulting sell-side speculation, Jefferies analyst Brian Tanquilut tells investors in a research note. With no Amazon pharmacy entry announced one week removed from the holiday, the analyst believes investor sentiment over the drug supply chain may gradually improve, at least in the near-term. He notes that the price-to-earnings multiples of Walgreens Boots Alliance (WBA) and CVS Health (CVS) have already declined amid speculation of an Amazon entry. Tanquilut acknowledges, however, that the Amazon overhang will not completely go away. The analyst has Buy ratings on UnitedHealth (UNH) and Walgreens, and Hold ratings on AmerisourceBergen (ABC), Cardinal Health (CAH), CVS and McKesson (MCK).
11/30/17
MKMP
11/30/17
NO CHANGE
Target $1350
MKMP
Buy
Amazon.com price target raised to $1,350 from $1,275 at MKM Partners
MKM Partners analyst Rob Sanderson raised his price target on Amazon to $1,350 and kept his Buy rating, keeping his view of the company as "the best long-term growth story available to large-cap investors today". Sanderson notes that the trend of AWS margin expansion will continue over the coming quarters. The analyst also believes that management can and should continue to reinvest aggressively, adding that "we are still not holding our breath on profits" despite the "richer" business mix.
11/30/17
RBCM
11/30/17
NO CHANGE
RBCM
Amazon.com's AWS offers scale and traction across verticals, says RBC Capital
RBC Capital analyst Mark Mahaney reflects on Amazon.com's AWS event that was much wider attended that in recent years. Mahaney says the company's presentation "highlighted the public cloud's significant appeal in organizations that span nearly every industry vertical". The analyst notes that Amazon's technical prowess make it a clear industry leader as evidenced by AWS expanding its market segment share by 5 points to 44%.
12/01/17
BMOC
12/01/17
UPGRADE
Target $142
BMOC
Outperform
VMware upgraded to Outperform at BMO Capital on faster computing growth
As reported earlier, BMO Capital analyst Keith Bachman upgraded VMware (VMW) to Outperform from Market Perform and raised his price target to $142 from $136. Bachman says the company is benefiting from improved on-premise spending trends, increasing his projections for the overall FY19 computing spend to grow 3% versus prior forecast of 1-2% decline. The analyst also says that management is being conservative in suggesting that the partnership with AWS (AMZN) would not generate returns for the next 2 years after attending AWS re:Invent this week.

TODAY'S FREE FLY STORIES

MGPI

MGP Ingredients

$74.01

0.25 (0.34%)

13:13
12/12/17
12/12
13:13
12/12/17
13:13
Conference/Events
MGP Ingredients management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

13:05
12/12/17
12/12
13:05
12/12/17
13:05
General news
30-Yr Bond Auction Coupon Rate data reported »

30-Yr Bond Auction Coupon…

13:05
12/12/17
12/12
13:05
12/12/17
13:05
General news
30-Yr Bond Auction Total Amount data reported »

30-Yr Bond Auction Total…

RIOT

Riot Blockchain

$23.08

7.22 (45.52%)

13:05
12/12/17
12/12
13:05
12/12/17
13:05
Options
Riot Blockchain Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$21.88

-0.175 (-0.79%)

13:03
12/12/17
12/12
13:03
12/12/17
13:03
Hot Stocks
Twitter adds plus button to simplify making Tweet threads »

Twitter said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

LLY

Eli Lilly

$86.39

-0.28 (-0.32%)

13:03
12/12/17
12/12
13:03
12/12/17
13:03
Hot Stocks
Eli Lilly Canada announces approval of Entuzity KwikPen »

Eli Lilly Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 18

    Jan

  • 31

    Jan

FDC

First Data

$16.60

0.175 (1.07%)

13:02
12/12/17
12/12
13:02
12/12/17
13:02
Conference/Events
First Data management to meet with Craig-Hallum »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 14

    Dec

WLL

Whiting Petroleum

$24.33

-1.2431 (-4.86%)

13:01
12/12/17
12/12
13:01
12/12/17
13:01
Downgrade
Whiting Petroleum rating change  »

Whiting Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
12/12/17
12/12
12:55
12/12/17
12:55
Conference/Events
FCC to ho ld a council meeting »

The Communications…

RPD

Rapid7

$18.77

0.03 (0.16%)

12:55
12/12/17
12/12
12:55
12/12/17
12:55
Conference/Events
Rapid7 to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

EPAY

Bottomline Technologies

$33.86

0.08 (0.24%)

12:54
12/12/17
12/12
12:54
12/12/17
12:54
Conference/Events
Bottomline Technologies management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$267.13

0.82 (0.31%)

12:51
12/12/17
12/12
12:51
12/12/17
12:51
Hot Stocks
Senator Paul says tax cuts 'are never the problem' »

Senator Rand Paul just…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$267.13

0.82 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:50
12/12/17
12/12
12:50
12/12/17
12:50
General news
Senator Rand Paul tweet »

Senator Rand Paul tweet…

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.94

0.63 (0.24%)

12:45
12/12/17
12/12
12:45
12/12/17
12:45
Hot Stocks
Senator Paul tweets opposition to bills that add to deficit »

Senator Rand Paul just…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.94

0.63 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$157.33

1.92 (1.24%)

12:45
12/12/17
12/12
12:45
12/12/17
12:45
Options
IBM call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

12:35
12/12/17
12/12
12:35
12/12/17
12:35
General news
Treasury 30-year auction preview: the auction is likely to see average results »

Treasury 30-year auction…

KMT

Kennametal

$47.39

1.43 (3.11%)

12:20
12/12/17
12/12
12:20
12/12/17
12:20
Earnings
Kennametal sees FY21 adjusted sales growing to $2.5B-$2.6B »

Sees adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

KMX

CarMax

$67.59

-0.38 (-0.56%)

12:20
12/12/17
12/12
12:20
12/12/17
12:20
Options
Short-term put buying in Carmax »

Short-term put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

KMT

Kennametal

$47.38

1.415 (3.08%)

12:18
12/12/17
12/12
12:18
12/12/17
12:18
Earnings
Kennametal sees FY18 adjusted sales $2.2B-$2.275B, consensus $2.24B »

Sees FY18 adjusted gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

$NSD

NASDAQ Market Internals

12:17
12/12/17
12/12
12:17
12/12/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
12/12/17
12/12
12:16
12/12/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNF

FNF Group

$40.39

-0.24 (-0.59%)

12:15
12/12/17
12/12
12:15
12/12/17
12:15
Conference/Events
FNF Group management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

12:10
12/12/17
12/12
12:10
12/12/17
12:10
Conference/Events
Morgan Stanley consumer/tobacco analyst has an analyst/industry conference call »

U.S. Food &…

VLKAY

Volkswagen

$40.48

0.38 (0.95%)

12:10
12/12/17
12/12
12:10
12/12/17
12:10
Periodicals
VW-owned Scania appeals EUR880M EU fine over price fixing, Reuters reports »

Scania, which is owned by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.37

-0.035 (-0.65%)

12:10
12/12/17
12/12
12:10
12/12/17
12:10
Options
Change of sentiment in AK Steel »

Change of sentiment in AK…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.